DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

RecruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
AI (Artificial Intelligence)Pulmonary Nodule, SolitaryPulmonary Nodule, MultipleLung Cancer
Trial Locations (10)

Unknown

RECRUITING

Betsi Cadwaladr University Health Board, Bangor

RECRUITING

Frimley Health NHS Foundation Trust (Wexham Park Hospital), Frimley

RECRUITING

Leeds Teaching Hospitals NHS Trust, Leeds

RECRUITING

King's College Hospital NHS Foundation Trust, London

RECRUITING

Royal Free Hospital, London

RECRUITING

St. George's University Hospitals NHS Foundation Trust, London

RECRUITING

The Royal Marsden NHS Foundation Trust, London

RECRUITING

University College London Hospitals NHS Foundation Trust, London

RECRUITING

Nottingham University Hospitals NHS Trust, Nottingham

RECRUITING

Oxford University Hospitals NHS Foundation Trust, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Optellum Ltd.

UNKNOWN

lead

Nottingham University Hospitals NHS Trust

OTHER

NCT05389774 - DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution | Biotech Hunter | Biotech Hunter